Printer Friendly

STERLING WINTHROP AND ELF SANOFI ANNOUNCE FINAL AGREEMENT FOR JOINT DEVELOPMENT, COMMERCIALIZATION OF TWO AGENTS WITH BRISTOL-MYERS SQUIBB

 NEW YORK, Aug. 2 /PRNewswire/ -- Sterling Winthrop and Elf Sanofi, who forged their Sanofi Winthrop alliance in 1991, announced today the signing of final agreements to jointly develop and market two promising cardiovascular compounds with Bristol-Myers Squibb Company (NYSE: BMY). Preliminary agreements were announced June 1.
 The worldwide strategic cooperative effort involves the joint development and commercialization of an Elf Sanofi angiotensin II receptor antagonist for the treatment of hypertension, and possibly other cardiovascular disorders, and clopidogrel, a novel antithrombotic agent for potential prevention of heart attack, stroke and peripheral arterial disease, which is currently being developed by the Elf Sanofi/Sterling Winthrop alliance.
 The angiotensin II receptor antagonist is in Phase II clinical trials in Europe and entering Phase II trials in the United States. It is expected to offer an advantage over several types of drugs now available for treating hypertension. Clopidogrel, an antithrombotic agent, is in Phase III clinical trials worldwide. Potential indications include prevention of secondary myocardial infarction, stroke and peripheral arterial disease.
 Development activities for the two products will be shared by the companies. Sterling Winthrop Pharmaceuticals Research Division and Sanofi Research will continue to lead development efforts for clopidogrel and Bristol-Myers Squibb Pharmaceutical Research Institute will lead the development effort for the angiotensin II receptor antagonist. Upon regulatory approval, marketing for each country will be handled on a country by country basis, and may include co-marketing, co-promotion and joint venture entity marketing.
 Headquartered in New York City and Paris, Sterling Winthrop and Elf Sanofi develop, manufacture and market pharmaceutical products. These products are marketed worldwide through the Sanofi Winthrop alliance. The companies' research and development efforts are focused in: diagnostic imaging, oncology, chronic inflammatory diseases, cardiovascular disease, endocrine and metabolic diseases and disorders of the central nervous system.
 -0- 8/2/93
 /CONTACT: Carol J. Perlman, 212-907-2724, or Terry G. Kelley, 212- 907-3009, both of Sterling Winthrop/
 (BMY)


CO: Sterling Winthrop Inc.; Elf Sanofi; Bristol-Myers Squibb Company ST: New York, New Jersey IN: MTC SU:

PS-MP -- NY022 -- 8255 08/02/93 10:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 2, 1993
Words:340
Previous Article:BED BATH & BEYOND FILES REGISTRATION STATEMENT FOR A SECONDARY OFFERING
Next Article:THE ZWEIG TOTAL RETURN FUND, INC. DECLARES MONTHLY DISTRIBUTION
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters